FUJI YAKUHIN CO., LTD.
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- Private
- Established
- 1930-02-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.fujiyakuhin.co.jp
Clinical Trials
25
Active:2
Completed:15
Trial Phases
4 Phases
Phase 1:4
Phase 2:11
Phase 3:5
+1 more phases
Drug Approvals
2
NMPA:2
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (22 trials with phase data)• Click on a phase to view related trials
Phase 2
11 (50.0%)Phase 3
5 (22.7%)Phase 1
4 (18.2%)Not Applicable
2 (9.1%)Study of FFI-1010 in Pediatric Kidney Disease
Phase 3
Completed
- Conditions
- Children Under 18 Years Old With Kidney Disease
- Interventions
- First Posted Date
- 2017-11-17
- Last Posted Date
- 2019-12-11
- Lead Sponsor
- Fuji Yakuhin Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT03345316
- Locations
- 🇯🇵
Fuji Yakuhin Investigational sites, Tokyo, Japan
Benzbromarone-Controlled, Double-Blind, Comparative Study of FYU-981 in Hyperuricemia With or Without Gout
Phase 3
Completed
- Conditions
- Hyperuricemia With or Without Gout
- Interventions
- First Posted Date
- 2017-04-04
- Last Posted Date
- 2018-09-26
- Lead Sponsor
- Fuji Yakuhin Co., Ltd.
- Target Recruit Count
- 201
- Registration Number
- NCT03100318
- Locations
- 🇯🇵
Tokyo, Tokyo, Japan
Study of FYU-981 in Hyperuricemia With or Without Gout
- First Posted Date
- 2016-12-30
- Last Posted Date
- 2018-12-06
- Lead Sponsor
- Fuji Yakuhin Co., Ltd.
- Target Recruit Count
- 330
- Registration Number
- NCT03006445
Mass Balance Study of FYU-981
Phase 2
Completed
- Conditions
- Healthy Male Subjects
- Interventions
- Drug: 14C-FYU-981
- First Posted Date
- 2016-09-15
- Last Posted Date
- 2018-08-21
- Lead Sponsor
- Fuji Yakuhin Co., Ltd.
- Target Recruit Count
- 6
- Registration Number
- NCT02901366
Study of FYU-981 in Hyperuricemia (Effect on Two Hyperuricemic Types)
- First Posted Date
- 2016-07-19
- Last Posted Date
- 2018-08-21
- Lead Sponsor
- Fuji Yakuhin Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT02837198
- Prev
- 1
- 2
- 3
- Next
News
Hyperuricemia Pipeline Shows Promise with 15+ Emerging Therapies in Development
Global hyperuricemia pipeline comprises 12+ key companies developing 15+ treatment therapies across various clinical stages, according to DelveInsight's 2025 report.